You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Drug Price Trends for NEOMYCIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for NEOMYCIN

Average Pharmacy Cost for NEOMYCIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
NEOMYCIN-POLYMYXIN-HC EAR SUSP 61314-0645-11 4.08640 ML 2025-12-17
NEOMYCIN-POLY-HC EYE DROPS 61314-0641-75 18.39787 ML 2025-12-17
NEOMYCIN-POLYMYXIN-HC EAR SUSP 24208-0635-62 4.08640 ML 2025-12-17
NEOMYCIN 500 MG TABLET 00093-1177-01 0.93951 EACH 2025-12-17
NEOMYCIN-POLYMYXIN-HC EAR SOLN 24208-0631-10 5.31822 ML 2025-12-17
NEOMYCIN 500 MG TABLET 62135-0443-90 0.93951 EACH 2025-12-17
NEOMYCIN 500 MG TABLET 73473-0901-05 0.93951 EACH 2025-12-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NEOMYCIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
NEOMYCIN/POLYMYXIN B SO4/GRAMICIDIN OPH SOLN Golden State Medical Supply, Inc. 24208-0790-62 10ML 45.95 4.59500 ML 2023-06-15 - 2028-06-14 FSS
NEOMYCIN-POLYMYXIN-HC SUSP,OTIC Rising Pharma Holding, Inc 64980-0448-01 10ML 26.26 2.62600 ML 2023-01-01 - 2026-05-31 FSS
NEOMYCIN-POLYMYXIN-HC SUSP,OTIC Rising Pharma Holding, Inc 64980-0448-01 10ML 15.82 1.58200 ML 2024-01-01 - 2026-05-31 FSS
NEOMYCIN-BACITRACIN-POLYMYXIN OINT,OPH Rising Pharma Holding, Inc 16571-0754-53 3.5GM 26.00 7.42857 GM 2022-10-08 - 2026-05-31 FSS
NEOMYCIN-BACITRACIN-POLYMYXIN OINT,OPH Rising Pharma Holding, Inc 16571-0754-53 3.5GM 14.17 4.04857 GM 2023-01-01 - 2026-05-31 FSS
NEOMYCIN-BACITRACIN-POLYMYXIN OINT,OPH Rising Pharma Holding, Inc 16571-0754-53 3.5GM 11.79 3.36857 GM 2024-01-01 - 2026-05-31 FSS
NEOMYCIN-POLYMYXIN-HC SUSP,OTIC Rising Pharma Holding, Inc 64980-0448-01 10ML 35.92 3.59200 ML 2022-10-08 - 2026-05-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NEOMYCIN

Last updated: July 27, 2025

Introduction

Neomycin, an aminoglycoside antibiotic, is primarily used to treat bacterial infections, notably in gastrointestinal decontamination, ocular infections, and as an ingredient in certain topical formulations. Given its longstanding presence in the healthcare landscape, understanding the current market dynamics and future price trajectories of neomycin is essential for pharmaceutical companies, healthcare providers, and investors aiming to navigate this segment effectively.

Market Overview

Global Demand and Usage Trends

The global demand for neomycin remains steady, driven primarily by its use in ophthalmology, dermatology, and gastrointestinal applications. Market reports reveal that while newer antibiotics have emerged, neomycin retains a niche due to its cost-effectiveness and established efficacy profile. The drug’s utilization is closely linked to infection rates, healthcare infrastructure, and regulatory approvals across markets.

Regional Market Dynamics

  • North America: Extensive healthcare infrastructure and widespread use in ophthalmic preparations sustain high demand. Regulatory controls, especially concerning ototoxicity and nephrotoxicity risks, influence formulations and prescribing habits.
  • Europe: Similar trends as North America, with a focus on topical formulations. Stringent regulations necessitate precise quality standards.
  • Asia-Pacific: Rapidly expanding healthcare systems and a high burden of infectious diseases bolster demand. Cost considerations favor generic formulations.
  • Emerging Markets: Increasing access to essential medicines further propels demand, although supply chain and regulatory hurdles may influence market penetration.

Market Drivers

  1. Ageing Population and Rising Infection Rates: Older populations are more susceptible to bacterial infections that require antibiotic intervention, boosting demand.
  2. Expanding Ophthalmic and Topical Uses: The growth of eye care and dermatology markets increases utilization.
  3. Cost-Effectiveness of Generic Neomycin: The availability of affordable generic options sustains its popularity, especially in price-sensitive markets.
  4. Increasing Healthcare Infrastructure in Developing Countries: Enhanced access encourages broader use of established antibiotics.

Market Restraints and Challenges

  • Toxicity Concerns: Neomycin's potential ototoxicity and nephrotoxicity restrict chronic or systemic use, leading to cautious prescribing.
  • Regulatory Limitations: Stricter regulations and safety warnings, especially in developed countries, can limit market expansion.
  • Competition: Replacement by broader-spectrum or newer antibiotics with improved safety profiles reduces reliance on neomycin.
  • Antimicrobial Stewardship Initiatives: Drive towards minimizing antibiotic use to combat resistance may curtail demand for older antibiotics like neomycin.

Pricing Landscape

Current Pricing Dynamics

Neomycin's pricing varies significantly based on formulation, concentration, source, and geographic location. Generic forms dominate in price-sensitive markets, with wholesale prices often substantially lower than branded equivalents. In developed nations, government tenders and reimbursement policies influence retail prices.

Factors Influencing Pricing

  • Regulatory Standards: Compliance costs impact manufacturing expenses and, consequently, pricing.
  • Formulation Type: Topical formulations (ointments, creams) are generally less expensive than injectable forms.
  • Market Competition: A higher number of suppliers suppresses prices, boosting affordability.
  • Supply Chain Constraints: Raw material costs, especially for specialized amino sugars, impact the final price.
  • Patent Status: As a longstanding generic drug, neomycin faces little to no patent restrictions, maintaining competitiveness.

Forecasting Price Trends

Near-term Outlook (Next 3-5 years)

  • Stability or Slight Decline in Price: Due to intense generic competition and increased manufacturing efficiencies, prices are likely to remain stable or decline marginally.
  • Regional Variations: In high-income markets, prices may stabilize owing to regulatory compliance costs, while developing markets could see further reductions due to increased competition.

Long-term Price Projections (5-10 years)

  • Potential Moderation: As newer antibiotics with improved safety profiles gain adoption, demand for neomycin could diminish, exerting downward pressure on prices.
  • Impact of Biosimilars or Alternatives: While unlikely for small molecules like neomycin, advancements could influence the availability and pricing landscape.
  • Regulatory and Safety Pressures: Heightened safety concerns may restrict usage, impacting volume and pricing power.

Market Opportunities and Strategic Recommendations

  1. Focus on Biopharmaceutical Formulations: Developing or investing in formulations with improved safety profiles may enable market differentiation.
  2. Explore New Delivery Systems: Targeted delivery platforms could expand application scopes, particularly in ophthalmic or topical segments.
  3. Invest in Quality and Compliance: Meeting international standards can open access to regulated markets, commanding premium pricing.
  4. Monitor Regulatory Changes Closely: Staying ahead of safety warnings and compliance requirements can prevent market disruptions.

Conclusion

Neomycin remains a key component within the broader antibiotic market, especially in topical and ophthalmic formulations. Its mature status and generic prevalence contribute to stable, price-sensitive market conditions, with a gradual trend toward declining prices driven by competition and evolving medical practices. Stakeholders should leverage opportunities in formulation innovation and regulatory compliance to sustain profitability amid a landscape shifting toward newer agents with better safety and efficacy profiles.


Key Takeaways

  • Neo mycin's global demand remains stable but faces competitive and safety-related pressures.
  • Price projections suggest stability in the short term with gradual declines over the longer term.
  • Market growth is primarily driven by demand in ophthalmic, dermatological, and gastrointestinal applications.
  • Strategies focusing on formulation innovation and regulatory adherence can create competitive advantages.
  • The evolving antimicrobial landscape demands continuous monitoring to mitigate risks and capitalize on opportunities.

FAQs

1. What are the primary clinical uses of neomycin today?
Neomycin is predominantly used topically in dermatology, ophthalmology, and gastrointestinal decontamination. Its systemic use is limited due to toxicity risks.

2. How does the safety profile of neomycin influence its market?
Concerns over ototoxicity and nephrotoxicity restrict systemic use, which constrains growth but sustains demand for topical and ophthalmic formulations.

3. What are the main factors impacting neomycin's pricing in the current market?
Factors include competition among generics, formulation types, regulatory compliance costs, and regional economic conditions.

4. Is there potential for new formulations or delivery systems of neomycin?
Yes. Innovations such as sustained-release topical applications or targeted delivery methods might expand its use and improve safety, influencing pricing and market positioning.

5. What future trends could affect the demand for neomycin?
The development of newer antibiotics with enhanced safety profiles, antimicrobial stewardship policies, and regulatory restrictions could reduce demand over time.


Sources
[1] Global Market Insights, “Antibiotics Market Size & Trends,” 2022.
[2] World Health Organization, “Antimicrobial Resistance and Antibiotic Consumption,” 2021.
[3] U.S. Food and Drug Administration, “Guidance on Ototoxic and Nephrotoxic Antibiotics,” 2020.
[4] MarketWatch, “Pharmaceutical Price Trends,” 2022.
[5] Reports and data from leading pharmaceutical market research firms, 2021-2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.